Datapoint: Scilex Sues Generic Pain Patch Challenger

Scilex Pharmaceutics, Inc. is suing Apotex Inc. over the Canadian drugmaker’s developing lidocaine patch, a generic challenger to Scilex’s ZTlido. Scilex says Apotex is violating three of ZTlido’s patents, centering around the patch’s non-aqueous lidocaine delivery. In the U.S., ZTlido is approved for the treatment of post-herpetic neuralgia, an indication for which it holds covered or better status for 57% of all insured lives under the pharmacy benefit. 10.6% of covered lives have preferred access to ZTlido without utilization management restrictions.

SOURCE: MMIT Analytics, as of 6/29/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 1

Datapoint: BMS Asks Supreme Court to Rehear CAR-T Dispute

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 30

Datapoint: New Startup Insurer to Expand to Six More States

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 29

Datapoint: FDA Approves Lilly’s Interchangeable Insulin

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today